Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Quantbot Technologies LP acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 15,425 shares of the company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Xeris Biopharma by 7.3% during the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after acquiring an additional 519,897 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Xeris Biopharma by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock valued at $278,000 after purchasing an additional 10,632 shares during the period. Simplicity Wealth LLC acquired a new stake in Xeris Biopharma in the 2nd quarter valued at about $27,000. Bank of New York Mellon Corp increased its position in Xeris Biopharma by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock worth $964,000 after buying an additional 80,015 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Xeris Biopharma by 4,512.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock valued at $37,000 after buying an additional 15,929 shares during the period. 42.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on XERS shares. Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Monday, November 11th. HC Wainwright increased their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Trading Down 1.6 %

Shares of NASDAQ XERS opened at $3.67 on Friday. The business’s 50 day moving average is $3.15 and its 200-day moving average is $2.69. The firm has a market cap of $547.12 million, a P/E ratio of -8.16 and a beta of 2.65. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.87.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.